Table 5.
CAM subgroup analysis: transplant-free survival vs. death/transplanted
| n | Transplant-free survival | n | Death/transplanted | P value | |
|---|---|---|---|---|---|
| Age, median | 10 | 46.0 | 30 | 40.0 | 0.66 |
| Sex (%) | 10 | 30 | |||
| Female | 5 (50) | 19 (63) | 0.48 | ||
| Male | 5 (50) | 11 (37) | |||
| Race (Caucasian) (%) | 10 | 4 (40) | 30 | 22 (73) | 0.11 |
| Body mass index (BMI), median | 6 | 25.4 | 20 | 30.8 | 0.03 |
| Laboratories, median [IQR] | 10 | 30a | |||
| ALT (IU/l) | 1,149 [849–2,447] | 602.5 [269–1,145] | 0.08 | ||
| AST (IU/l) | 1,200.5 [549–1,948] | 558.0 [205–1,537] | 0.21 | ||
| Alkaline phosphate (IU/l) | 148 [104–250] | 121 [102–168] | 0.37 | ||
| INR | 1.8 [1.7–2.1] | 3.2 [2.6–4.3] | <0.01 | ||
| Platelet count (×1,000/mm3) | 190.5 [118–290] | 141 [107–202] | 0.11 | ||
| Bilirubin (mg/dl) | 15.4 [9.9–23.4] | 18.6 [12.3–28.4] | 0.44 | ||
| MELD | 24.2 [23.3–27.8] | 33.9 [29.4–39.5] | 0.01 | ||
| Pattern of injury/R score (%) | 10 | 28 | 0.11 | ||
| Hepatocellular | 9 (90) | 22 (79) | |||
| Mixed | 0 (0) | 6 (21) | |||
| Cholestatic | 1 (10) | 0 (0) | |||
| Degree of injury—ALI/ALF (%) | 10 | 30 | 0.01 | ||
| ALI | 4 (40) | 1 (3) | |||
| ALI progressed to ALF | 1 (10) | 3 (10) | |||
| ALF | 5 (50) | 26 (87) |
ALF, acute liver failure; ALI, acute liver injury; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CAM, complementary and alternative medicine; INR, international normalized ratio; IQR, interquartile range; MELD, Model of End-Stage Liver Disease.
a
Incomplete data on all patients. Sample size ranges for subset of data Death/Transplanted n=28–30.